In our study, treatment with the new therapeutic regimen led to 11 (91.7%) patients achieving objective responses by MRI, while previous studies have revealed that NET achieves an objective response rate of approximately 60% in HR-positive, HER2-negative breast cancer patients (Sella et al., 2021). This evidence concerns the gene ERBB2 and breast cancer.